ALDX Earnings Aldeyra Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Net income
ROE
Quarterly results
EPS
Net income
ROE
Reported EPS history
1–41 of 41
| Q2 2026 | 2026-06-30 | -0.09 | 2026-08-06 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.06 | 2026-05-07 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | -0.10 | 2026-02-27 | 10-K |
| FY 2025 | 2025-12-31 | -0.56 | 2026-02-27 | 10-K |
| Q3 2025 | 2025-09-30 | -0.13 | 2025-11-05 | 10-Q |
| Q2 2025 | 2025-06-30 | -0.16 | 2025-08-07 | 10-Q |
| Q1 2025 | 2025-03-31 | -0.17 | 2025-05-14 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | -0.27 | 2025-02-28 | 10-K |
| FY 2024 | 2024-12-31 | -0.94 | 2025-02-28 | 10-K |
| Q3 2024 | 2024-09-30 | -0.25 | 2024-11-07 | 10-Q |
| Q2 2024 | 2024-06-30 | -0.28 | 2024-08-01 | 10-Q |
| Q1 2024 | 2024-03-31 | -0.14 | 2024-05-02 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | -0.08 | 2024-03-07 | 10-K |
| FY 2023 | 2023-12-31 | -0.64 | 2024-03-07 | 10-K |
| Q3 2023 | 2023-09-30 | -0.14 | 2023-11-03 | 10-Q |
| Q2 2023 | 2023-06-30 | -0.15 | 2023-08-03 | 10-Q |
| Q1 2023 | 2023-03-31 | -0.27 | 2023-05-04 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | -0.22 | 2023-03-09 | 10-K |
| FY 2022 | 2022-12-31 | -1.06 | 2023-03-09 | 10-K |
| Q3 2022 | 2022-09-30 | -0.25 | 2022-11-10 | 10-Q |
| Q2 2022 | 2022-06-30 | -0.30 | 2022-08-05 | 10-Q |
| Q1 2022 | 2022-03-31 | -0.29 | — | — |
| FY 2021 | 2021-12-31 | -1.07 | — | — |
| Q3 2021 | 2021-09-30 | -0.27 | — | — |
| Q2 2021 | 2021-06-30 | -0.28 | — | — |
| Q1 2016 | 2016-03-31 | -0.51 | 2016-05-09 | 10-Q |
| Q4 2015 (derived) | 2015-12-31 | -0.46 | 2016-03-30 | 10-K |
| FY 2015 | 2015-12-31 | -1.40 | 2016-03-30 | 10-K |
| Q3 2015 | 2015-09-30 | -0.35 | 2015-11-13 | 10-Q |
| Q2 2015 | 2015-06-30 | -0.27 | 2015-08-14 | 10-Q |
| Q1 2015 | 2015-03-31 | -0.32 | 2015-05-14 | 10-Q |
| Q4 2014 (derived) | 2014-12-31 | 2.87 | 2015-03-23 | 10-K |
| FY 2014 | 2014-12-31 | -3.09 | 2015-03-23 | 10-K |
| Q3 2014 | 2014-09-30 | -0.36 | 2014-11-12 | 10-Q |
| Q2 2014 | 2014-06-30 | -1.56 | 2014-08-07 | 10-Q |
| Q1 2014 | 2014-03-31 | -4.04 | 2014-06-11 | 10-Q |
| Q4 2013 (derived) | 2013-12-31 | 10.70 | — | — |
| FY 2013 | 2013-12-31 | -17.61 | — | — |
| Q3 2013 | 2013-09-30 | -9.81 | — | — |
| Q2 2013 | 2013-06-30 | -5.47 | — | — |
| Q1 2013 | 2013-03-31 | -13.03 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.